30.05.2025

Top Stock Recommendations for May 2025: Which Titles are Currently Interesting

Stock Recommendations for May 2025

In the past trading week, experts have recommended several stocks for purchase that are of interest to investors in the German-speaking area. Here are some of the recommended stocks and the reasons why they are considered attractive investment options:

1. Airbnb

Airbnb is recommended by experts like Caio Reimertshofer, as the company plans to expand its business model. This expansion could include new services in the travel sector or offerings for hosts, providing long-term growth potential.

2. Visa

Visa is another recommended company, although it incurred losses in April. The currency loss from the US dollar may pose a challenge for German investors.

3. Fresenius

The Swiss bank UBS has maintained its rating for Fresenius at “Buy”, indicating confidence in the company.

4. thyssenkrupp

The Baader Bank has maintained thyssenkrupp at “Buy” with a target price of 8 Euros, suggesting positive expectations for the company.

5. BMW

The US analysis firm Bernstein Research has maintained its rating for BMW at “Outperform” with a target price of 92 Euros, indicating the company’s strong position in the automotive market.

6. Novo Nordisk

Deutsche Bank Research has maintained its rating for Novo Nordisk at “Buy” with a target price of 750 Danish Kroner, indicating positive developments in the healthcare sector.

7. BASF

Bernstein Research has maintained its rating for BASF at “Outperform” with a target price of 60 Euros, highlighting the company’s strong position in the chemical industry.

8. Polaris

Morningstar classifies Polaris as significantly undervalued and offers an attractive value-for-money ratio. The company benefits from its operational excellence and acquisition strategy.

9. Nike

Nike is another undervalued stock recommended by Morningstar. The company is known for its strong brand position and ability to innovate.

10. Pfizer

Pfizer is also recommended by Morningstar, as it has a strong position in the pharmaceutical sector and benefits from its research and development.

These recommendations can help investors make informed decisions and diversify their portfolios. However, it is important to conduct your own research and consider the current market situation.